|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
BEFREE |
Moreover, TAS-121 displayed antitumor activity in SW48 (<i>EGFR</i> G719S) and NCI-H1975 (<i>EGFR</i> L858R/T790M) xenograft models, and achieved an objective response in patients with NSCLC with <i>EGFR</i> mutations including G719A mutation.
|
30872380 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
BEFREE |
Herein, we discuss the case of a patient with advanced NSCLC harboring both the uncommon EGFR G719S and the KRAS G12C mutations, who was treated for 9 years with erlotinib achieving a long-term survival.
|
29748019 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
BEFREE |
Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report.
|
29245278 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
BEFREE |
Consistently, afatinib was clinically effective for the treatment of NSCLC harboring G719C and S768I mutations of EGFR.
|
27794398 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
BEFREE |
The non-small cell lung cancer (NSCLC)-associated EGFR mutants, L858R and G719S, are constitutively active and oncogenic.
|
22349823 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
|
21841502 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
|
19536777 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
|
20479403 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
|
19922469 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
|
19671738 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
|
18199554 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
|
16011858 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
CLINVAR |
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.
|
15788655 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
|
15710947 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
|
16115929 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
|
15118073 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
CLINVAR |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
|
15118073 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
|
15118125 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
CausalMutation
|
CLINVAR |
"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."
|
15329413 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
|
0.750 |
GeneticVariation
|
CLINVAR |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
|
15118125 |
2004 |